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Gene Editing refers to the process of making targeted modi-
fications to the genome, such as the deletion, insertion or 
replacement of targeted DNA sequences (Pan et al., 2011). 
Gene editing technologies fundamentally improve our ap-
proaches to biological basic research, gene therapy, genetic 
improvement, etc. In the field of stem cells, gene editing 
can be used to modulate cell fate, such as generation of in-
duced pluripotent stem cells (iPSCs) (Ding et al., 2015), 
cellular differentiation and transdifferentiation (Zhang et al., 
2014). In gene therapy, gene editing can be used to correct 
disease mutations in patient-derived cells, which holds great 
promise to cure related diseases in the future (Liu et al., 
2012; Liu et al., 2014). 
In recent years, ZFN (zinc-finger nucleases) and TALEN 
(transcription activator-like effector nucleases) have be-
come two representative site-specific nucleases for precise 
and efficient genome editing and show great potential in 
applications, while a third generation gene editing technol-
ogy, the CRISPR/Cas9 system (clustered regularly inter-
spaced short palindromic repeats/CRISPR-associated pro-
tein 9) triggered a revolution in genome editing (Cong et al., 
2013; Mali et al., 2013). As a simple, fast and highly effi-
cient approach, CRISPR/Cas9 has become a routine and 
indispensable tool for almost every biological or biomedical 
lab all over the world (Deng et al., 2015; Rong et al., 2014; 
Zhang and Zhou, 2014). CRISPR/Cas9 not only improves 
the speed and efficiency of gene editing, it also makes sig-
nificant advances towards tasks that are hard or impossible 
to accomplish using previous approaches, such as produc-
tion of transgenic pigs and non-human primates (Hai et al., 
2014; Niu et al., 2014), and whole genome screening for 
functional genes relevant to cancer or other diseases as well 
as for genes involved in drug resistance (Shen and Ou, 
2014; Zhou et al., 2014), etc. In May 2016, Gao et al. re-
ported an archaebacterium-derived DNA nuclease named 
NgAgo that could edit mammalian genomic DNA in a more 
precise and efficient manner (Gao et al., 2016). Although 
there are still controversies about this approach, it shone a 
light for the next generation of gene-editing techniques. 
In 2015, Dr. Junjiu Huang of Sun Yat-Sen University 
applied the CRISPR/Cas9 technology to take a lead in hu-
man embryo genome editing (Liang et al., 2015). In tripro-
nuclear (3PN) zygotes (byproducts of assisted reproduc-
tion), Dr. Huang edited an HBB gene that causes human 
β-thalassemia and sickle cell anemia, and found that 
CRISPR/Cas9 can correct HBB gene mutations in some 
zygotes. This milestone work was published in Protein & 
Cell and has attracted global attention across the whole field 
of life science.  
Some scientists criticized this work on the basis that 
‘gene editing of human embryo is unethical—it can perma-
nently modify human genes’, which has led to a global de-
bate on ‘gene editing in human embryos’ (Cyranoski, 2015; 
Cyranoski and Reardon, 2015; Zhang, 2015). The Wash-
ington Conference in December, 2015 also held a broad and 
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in-depth discussion on the topic of gene editing in human 
embryos. The conference reached an agreement that pre-
clinical research using human embryos, sperm cells and egg 
cells should not be paused or stopped, and that while ge-
nome editing in human embryos for basic research should 
be continued, it has to be in accordance with extensive eth-
ical approval and within the constraints of related laws and 
regulations. 
As early as February 2015, an overwhelming majority in 
the House of Commons of the United Kingdom had passed 
a resolution which allowed researchers to continue their 
research work on reproductive medical technologies of 
‘mitochondrial replacement therapy (MRT)’, making UK 
the first country to legalize ‘MRT’. Beyond this, on October 
19, 2016 at the American Society for Reproductive Medi-
cine Conference, a group led by Dr. Jin Zhang from the 
New Hope Fertility Center of America announced the birth 
of the world’s first three-parent baby in April 2016. 
Mutations in mitochondrial DNA (mtDNA) usually re-
sult in severe mitochondrial diseases. As mtDNA is inher-
ited from oocytes, descendants of female carriers of mtDNA 
mutations usually have a very high frequency of developing 
mitochondrial diseases. ‘MRT’ is a type of assisted repro-
ductive technology which replaces defective mitochondria 
in patients’ oocytes with ones from healthy female donors’ 
oocytes, while not changing the nuclear genomes of patients 
and their spouses. The resulting baby physiologically inher-
its genes from ‘three parents’—two mothers and one father. 
Meanwhile, by gender selection of healthy embryos (only 
preserving male embryos), ‘MRT’ can prevent passing mi-
tochondrial DNA-associated diseases to the next generation.   
Although some scientists remain skeptical about the eth-
ics and safety of this technology, it undoubtedly opens a 
new era of assisted reproductive medicine, and provides 
new perspectives and methods for the prevention of mito-
chondrial DNA-associated diseases. We will have to wait 
and see how future scientists further tackle problems in the 
basic science and clinical application of ‘human embryo 
gene editing’. 
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